Abivax (ABVX) surges 398.80% pre-market on positive Phase 3 trial results
-
最新报道：Abivax (ABVX) shares surged 398.80% in pre-market trading following positive Phase 3 trial results for its lead drug candidate. The biotech company reported significant efficacy in treating a chronic inflammatory disease, exceeding expectations in key endpoints. Analysts suggest the strong data could position the drug for accelerated regulatory approval and potential blockbuster status. The trial success marks a major milestone for Abivax, which had previously faced skepticism over its clinical pipeline. Market observers note the dramatic pre-market move reflects pent-up investor optimism after years of development. The company plans to submit full trial data for peer review and engage with regulators on next steps.
下一篇
Institutional Demand Shifts to Ethereum! U.S. President Donald Trump-Linked Enterprise Purchases Large Ethereum! Details Here
- World Liberty Financial (WLFI), the crypto project known for its links to former US Presid...
24小时热点
热点专题
417252